With the rapid rise of antibody drugs targeting immune checkpoints such as PD1/PDL-1 in the field of tumor therapy, more and more attention is being paid to the development of emerging drugs and immunotherapy. We are honored to invite scholars from domestic research institutions, high-level medicine, and experts from pharmaceutical CRO companies to share their insights on innovative drugs and tumor immunotherapy in the field of translational medicine on September 19th, in response to this hot topic. At that time, everyone will have a deeper understanding and discussion of cutting-edge issues in the fields of drug carrier design, humanized animal model construction, toxicity evaluation of artificial organ drugs, and AI guided medical care.

Perkin ElmerCase sharing:

Application of Multi label Imaging System for Tissue Slices - Research on Tumor Immunotherapy:

In their study, Pardoll et al. collected samples from lung cancer patients before and after immunotherapy with the PD-1 inhibitor Nivolumab. Opal multi label technology was used to label PD-L1, PD-1, CD8, FOXP3, CD68, CK target molecules, and the PerkinElmerVectra multispectral imaging analysis system was used to evaluate and analyze the patient's immune microenvironment, providing important support for later diagnosis and treatment plans. The results were published in The New England Journal of Medicine in April 2018.

Application of small animal live imaging system:

Nano or tissue engineering materials have shown great potential for application in biomedical research and drug development, attracting the attention of researchers in various interdisciplinary fields such as biology, medicine, and materials science. The live animal technology is mainly applied in the following fields: 1. Research and development of nanoprobes; 2. Evaluation of nano drug carriers; 3. Biocompatibility and safety evaluation of nanomaterials.

Research on nano drug carriers: The use of small animal in vivo imaging technology can monitor the distribution and targeting of nano carriers in real time, and evaluate the effectiveness of carrier design. (Green: tumor bioluminescence signal, red: particle fluorescence signal) Lijuan Zeng et al., Adv. Funct. Mater. 2016

As an open laboratory for translational medical imaging and detection, the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, has helped scientific researchers to complete many scientific research projects since its opening last year, published many high-level documents, and achieved numerous scientific research achievements. As an annual industry event, we would like to invite you to participate in the "Tumor Immunity and Personalized Medicine - the Second State Key Laboratory of Biochemical Engineering - Perkin Elmer Annual Conference of Translational Medicine" to be held at the Institute of Process Engineering, Chinese Academy of Sciences, Beijing, on September 19.

In order to strengthen academic exchanges and promote the development and progress of tumor immunology and personalized therapy, this conference invites domestic and foreign experts to further interpret the hot and difficult issues in this field, and will showcase the new frontier progress in the field of tumor immunology and personalized medicine. We sincerely invite you to attend this grand event and gather in Beijing! Looking forward to your attendance!